RxDoctor Payments Data

Susheel Dua, MD

Pain Medicine · Atlanta, GANPI 1467598904

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $23,495 of the $36,320 with a category attached, or 64.7%. Avanos Medical accounts for 80.5% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2019 at $16,909 and has fallen 95.4% since, to $785 in 2025. Among pain medicine clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$36,320in general payments, 2019–2025

Across 244 payments — averaging $148.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Avanos Medical$29K
  • Abbott$2K
  • Boston Scientific$1K
  • Collegium Pharmaceutical, Inc.$973
  • Medtronic$490
  • AbbVie$371
  • plus $2K from 21 others

What the payments were for

  • Speaking & faculty fees$23,49565%
  • Travel & lodging$7,04619%
  • Food & beverage$5,78016%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,320 in reported general payments places this provider in the 95th percentile of 203 pain medicine providers in Georgia.

See all pain medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$61,194
Medicare patients
380
Services billed
751

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl125$92,553
Xtampza ErOxycodone Myristate107$68,691
Buprenorphine207$55,225
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen600$39,942
OxycontinOxycodone Hcl54$33,465
MovantikNaloxegol Oxalate48$20,028
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen668$13,334
Fentanyl115$12,260
ButransBuprenorphine18$9,059
Gabapentin528$8,067
Pregabalin342$7,135
Oxycodone Hcl361$5,632
Morphine Sulfate ErMorphine Sulfate219$5,315
Lidocaine39$3,846
Celecoxib135$2,494

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$973$161,244232 claims
Redhill Biopharma Inc.Movantik$13$20,02848 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 203 pain medicine providers in Georgia.

Other pain medicine in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →